Shaped Docuseries Episode 2: Should the FDA approve MDMA-assisted therapy for PTSD?

MDMA, once hailed in the 1970s for its medical potential, was outlawed in 1985 over concerns of abuse. While it remains a Schedule I controlled substance under federal law, advocates and therapeutic companies continue to submit applications to the FDA for approved medical use, particularly for PTSD treatment.

In the second episode of the Regulatory Transparency Project’s three-part series, “Shaped,” experts across the legal and medical industries explore the difficult question at the heart of medical progress: How do we balance providing access to life-changing treatments with the duty to protect the consumer’s long-term safety?